Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis

Monitor this Company

WASHINGTON, Oct. 22 // -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day and six- month follow-up, reported Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, in Washington, D.C.

    Specifically, six-month clinical follow-up data from the 193-patient, single-center, prospective, single-blind study called TRIAS HR Pilot indicate:

    -- No statistically significant difference in the rate of major adverse

     cardiac events (MACE)

    -- At six-month follow-up, the majority of patients who received a Genous

     stent were on single antiplatelet therapy, while the majority of

     patients who received a Taxus stent were still on dual antiplatelet

     therapy

    -- One acute stent thrombosis in the Genous arm, while there was one acute,

     one subacute and one late stent thrombosis in the Taxus arm

    -- More instances of non-target vessel revascularization (non-TVR) in the

     Taxus arm

    "The much-needed alternative to drug-eluting stents may not be the next- generation drug-eluting stents," said de Winter. "Genous is a very promising, innovative device with a wide range of applications for physicians and many benefits to patients. The results of our pilot study fully support our rationale for the large-scale TRIAS study that will compare Genous to both drug-eluting and bare metal stents."

    For the TRIAS HR Pilot, high risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than 2.8 mm) and/or long lesions (greater than 20 mm) and/or chronic total occlusions.

    Genous is coated with an antibody to capture a patient's endothelial progenitor cells, and, therefore, accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of the Genous stent, EPCs can form an endothelial layer over the stent to provide protection against thrombus and minimize restenosis. The stent was developed by OrbusNeich, a global medical device company.

    For more information, call +31.20.56.67.883 or send an e-mail to trias@amc.nl.

    Media Contacts:

    David Schull

    Russo Partners LLC

    +1.212.845.4271 (office)

    +1.858.717.2310 (mobile)

    david.schull@russopartnersllc.com

    Benjamin Carmichael

    +1.212.845.4242

    benjamin.carmichael@russopartnersllc.com
Monitor this Company :
You will receive an email alert whenever there is a news item concerning this company.
Name Your Company
Email Address Position/Role


2001 - 2016 Lexdon Business Library
About TrustBase
Privacy Policy